We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

FARN Faron Pharmaceuticals Oy

14.00 (5.38%)
01 Dec 2023 - Closed
Delayed by 15 minutes
Faron Pharmaceuticals Oy Investors - FARN

Faron Pharmaceuticals Oy Investors - FARN

Share Name Share Symbol Market Stock Type
Faron Pharmaceuticals Oy FARN London Ordinary Share
  Price Change Price Change % Share Price Last Trade
14.00 5.38% 274.00 16:35:14
Open Price Low Price High Price Close Price Previous Close
260.00 260.00 260.00 274.00 260.00
more quote information »
Industry Sector

Top Investor Posts

Top Posts
Posted at 23/4/2022 17:56 by share23
Faron latest presentation. CFO mentions that they have hired new VP of investor relations to New York and that they are making Faron Wallstreet ready. Are they getting ready for an IPO to Nasdaq, New York? (around 4:00 minutes)Additionally CEO talks about potential licensing deal for Bexmarilimab and refers to other deals that have been made in the area which are billion-dollar milestone deals. CEO also says after mentioning the billion dollar deals: Happy to say there are number of companies discussing with us (around 19:00 minutes).Can't believe this company is so under the radar with so low share price.
Posted at 19/1/2021 16:36 by timbo003
Faron are presenting at the Proactive one2one investors forum this Thursday (21st January)

Click here to register
Posted at 25/10/2020 13:29 by sharesoc
Potential investors and current shareholders may be interested in our webinar with Faron Pharmaceuticals (FARN), 3 November 2020
Posted at 26/2/2020 23:31 by bwgs
Thank you for your reply.To date I have to say I'm very encouraged as an investor in the way Farn is moving.In respect of 3rd party funding, it may well be that Farn are being very cautious, and not willing to dilute to high heaven (which is what usually happens on AIM).Would be great to see this going back to £8+
Posted at 20/2/2020 11:59 by bioking
DNL about to explode , Institutional investor added 1 million shares this week . LOTS of BIG NEWS around the corner =10+ BAGGER GEM RALLLYYYYYYYYYYYY

Diurnal (DNL)
Market Cap £27 M
Price: 31p

Upcoming Catalysts:

MAA-Acceptance for Chronocort in February/March 2020

Alkindi approval in Israel expected in 2Q 2020

Alkindi approval in Australien expected in 2Q 2020

US-Partnership for Alkindi & Chronocort expected in 1H 2020

Alkindi & Chronocort Partnership for Asia für Japan und China

US-Approval for Alkindi expected in 4Q 2020

EU Approval for Chronocort expected in 4Q/1Q 2020/21

Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses
Posted at 28/11/2019 09:18 by hashertu
DL. I think there is disappointment that the IND did not include the use of Clevegen to treat investors who suffer from refractory apathy.
Posted at 26/11/2019 08:29 by daffodil4
The undisclosed investors in the latest placing presumably
all took under now they can sell on the
Helsinki Nasdaq without having to declare shortly...
Will those trades show on this site???? Thanks!
Posted at 11/10/2019 08:42 by hashertu
I went to Proactive Investor last night.
Markku (in Q&A) said that is possible that Clevegen could be available in the market as soon as 2023. I think it was said in the context of Colorectal cancer, where patients have failed all other lines of treatment, which would allow a significantly shorter approval process.
I asked him about the reason for calling the EGM so soon after the recent placing, and what was referred to in the Notice, section B, "events after preparation ...". Traumakine manufacturing is the reason.
At the EGM, they are seeking authority to issue 7.8m shares, and removing authority from 7.1m. Markku seemed to think it normal company practice.
I have not read all the small print, but suspect that the rules governing how they can issue those shares is changed. Or more importantly, to whom.
Markku is still very excited about Clevegen in his presentation.
If I had to hazard a guess (Markku did not say or hint), I would say that a partner has been lined up for Clevegen. As a minimum they will take a significant stake in Faron (up to 20%) and probably pay for some/all of the Clevegen program in isolation or in combination with their own drugs.
The conversations with the FDA/Traumakine/cortico steroids are quite advanced. The FDA have taken the Faron assessment of the use of CS and their effects very seriously. I got the impression that a statement was imminent.
Anyway, the cash from (possible) placing might be enough to test Traumakine with CS.
Posted at 25/5/2019 06:52 by dan1nat1
Lucky we didn't have a resignation then!Wichmann has a new role "Vice President, Financing and Investor Relations".His replacement "Hänninen" has come from a massive group that just so happen to be very active on the acquisition front... the time to be posting factually incorrect one line comments, based on an RNS you don't seem to understand.
Posted at 30/1/2019 11:58 by bioking
Only 31 million shares outstanding and almost 40% of these shares held by the 10 largest shareholder alone which didnt sell even after 90% drop .Stock coming from over 800p now trading at 55p .stock will rally if the Japan phase 3 results are positive which could come anytime now .

Marko Salmi 3 093 439
Aviva Investors Global Services Ltd. 1 518 814
Hargreave Hale Ltd. 1 475 875
Polar Capital LLP 1 452 381
Timo Kalevi Syrjälä 1 390 830
Juho Markku Jalkanen, MD 1 082 570
Rhenman & Partners Asset Management AB 759 265
Keskinäinen Eläkevakuutusyhtiö Ilmarinen 636 721
Hargreave Hale Ltd. (Venture Capital) 167 154
Amati Global Investors Ltd. (Venture Capital) 122 993

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |